(2R,3R,4R,5R)-8-(tert-butyldimethylsilanyloxy)-3-hydroxy-5-(4-methoxybenzyloxy)-2,4-dimethyloctanoic acid, 2,6-dimethylphenyl ester | 479673-24-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: (2R,3R,4R,5R)-8-(tert-butyldimethylsilanyloxy)-3-hydroxy-5-(4-methoxybenzyloxy)-2,4-dimethyloctanoic acid, 2,6-dimethylphenyl ester
• 英文别名: (2R, 3R, 4R, 5R)-8-(TERT-BUTYLDIMETHYLSILANYLOXY)-3-HYDROXY-5-(4-methoxybenzyloxy)-2,4-dimethyloctanoic acid, 2,6-dimethylphenyl ester；(2R,3R,4R,5R)-8-(tert-Butyldimethylsilanyloxy)-3-hydroxy-5-(4-methoxybenzyloxy)-2,4-dimethyloctanoic acid, 2,6-dimethylphenyl ester；(2,6-dimethylphenyl) (2R,3R,4R,5R)-8-[tert-butyl(dimethyl)silyl]oxy-3-hydroxy-5-[(4-methoxyphenyl)methoxy]-2,4-dimethyloctanoate
• CAS: 479673-24-0
• 化学式: C₃₂H₅₀O₆Si
• 分子量: 558.831
• InChiKey: LAJDGBMSVIVQHD-FDYRDFEWSA-N

物化性质

• 沸点：
  617.8±55.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.24
• 重原子数：
  39
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R,5R)-8-(tert-butyldimethylsilanyloxy)-3-hydroxy-5-(4-methoxybenzyloxy)-2,4-dimethyloctanoic acid, 2,6-dimethylphenyl ester 在 palladium 10% on activated carbon 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 生成 (2R,3R,4S,5R)-8-(tert-Butyl-dimethyl-silanyloxy)-3,5-dihydroxy-2,4-dimethyl-octanoic acid 2,6-dimethyl-phenyl ester
  参考文献：
  名称：

  [EN] ANALOGS OF DISCODERMOLIDE AND DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF SYNTHESIS THEREOF
  [FR] ANALOGUES DE DISCODERMOLIDE ET DE DICTYOSTATINE-1, INTERMEDIAIRES CORRESPONDANTS, ET PROCEDES DE SYNTHESE CORRESPONDANTS

  摘要：

  以下是该结构的化合物：其中R1为H、烷基基团、芳基、烯基基团、炔基基团或卤素原子；R2为H、烷基基团、芳基、苄基、三苄基、-SiRaRbRc、CH2ORd或CORe；Ra、Rb和Rc独立地为烷基基团或芳基；Rd为烷基基团、芳基、烷氧基烷基团、-RiSiRaRbRc或苄基，其中Ri为烷基烷基团；Re为烷基基团、烯丙基基团、苄基、芳基、烷氧基或-NRgRh，其中Rg和Rh独立地为H、烷基基团或芳基；R3为(CH2)n，其中n为0到5范围内的整数，-CH2CH(CH3)-、-CH=CH-、-CH=C(CH3)-或-C=-C-；R4为(CH2)p，其中p为4到12范围内的整数，-(CHRkl)yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5C(Rsl )=C(Rs2)C(Rs3)=C(Rs4)-、-(CHRk1 )yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5CH(Rs I)CH(Rs2)C(Rs3)=C(Rs4)-、-(CHRk1)yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRks)y5C(Rsl)=C(Rs2)CH(Rs3)CH(Rs4)-、-(CHRkI )yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5CH(Rsl)CH(Rs2)CH(Rs3)CH(R s4)-，其中y1和y2为1，y3、y4和y5独立地为0或1，Rk1、Rk2、Rk3、Rk4和Rk5独立地为H、CH3或OR2a，Rs1、Rs2、Rs3和Rs4独立地为H或CH3，其中R2a为H、烷基基团、芳基、苄基、三苄基、-SiRaRbRc、CH2ORd或CORe；R5为H或OR2b，其中R2b为H、烷基基团、芳基、芳基、苄基、三苄基、-SiRaRbRc、CH2ORd或CORe；前提是该化合物不是dictyostatin 1。

  公开号：

  WO2004022552A1
• 作为产物：
  描述：

  4-(叔丁基二甲基甲硅烷基)氧代-1-丁醇 在 锂硼氢 、 三氟甲磺酸二丁硼 、 三氧化硫吡啶 、 二异丁基氢化铝 、 戴斯-马丁氧化剂 、 三乙胺 、 N,N-二异丙基乙胺 、 lithium diisopropyl amide 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 (2R,3R,4R,5R)-8-(tert-butyldimethylsilanyloxy)-3-hydroxy-5-(4-methoxybenzyloxy)-2,4-dimethyloctanoic acid, 2,6-dimethylphenyl ester
  参考文献：
  名称：

  Discodermolide / Dictyostatin杂种：合成和生物学评估。

  摘要：

  [结构：见正文]已设计并合成了二编码器莫迪尔和双香豆素（3，26）的两个杂合类似物。这些是第一个discodermolide的大环类似物，并对其生物学活性进行了评估，并与线性discodermolide的类似物进行了比较。

  DOI：

  10.1021/ol026942l

文献信息

• Discodermolide/Dictyostatin Hybrids:  Synthesis and Biological Evaluation
  作者：Youseung Shin、Nakyen Choy、Raghavan Balachandran、Charitha Madiraju、Billy W. Day、Dennis P. Curran

  DOI：10.1021/ol026942l

  日期：2002.12.1

  [structure: see text] Two hybrid analogues of discodermolide and dictyostatin (3, 26) have been designed and synthesized. These are the first macrocyclic analogues of discodermolide and biological activities were evaluated and compared with linear discodermolide analogues.

  [结构：见正文]已设计并合成了二编码器莫迪尔和双香豆素（3，26）的两个杂合类似物。这些是第一个discodermolide的大环类似物，并对其生物学活性进行了评估，并与线性discodermolide的类似物进行了比较。
• [EN] ANALOGS OF DISCODERMOLIDE AND DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF SYNTHESIS THEREOF<br/>[FR] ANALOGUES DE DISCODERMOLIDE ET DE DICTYOSTATINE-1, INTERMEDIAIRES CORRESPONDANTS, ET PROCEDES DE SYNTHESE CORRESPONDANTS
  申请人：UNIV PITTSBURGH

  公开号：WO2004022552A1

  公开（公告）日：2004-03-18

  A compound of the following structure: wherein R1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom; R2 is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbRc, CH2ORd, or CORe; Ra, Rb and Rc are independently an alkyl group or an aryl group; Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -RiSiRaRbRc or a benzyl group, wherein Ri is an alkylene group; Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group; R3 is (CH2)n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=-C-; R4 is (CH2)p where p is an integer in the range of 4 to 12, -(CHRkl)yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5C(Rsl )=C(Rs2)C(Rs3)=C(Rs4)-, -(CHRk1 )yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5CH(Rs I)CH(Rs2)C(Rs3)=C(Rs4)-, -(CHRk1)yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRks)y5C(Rsl)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkI )yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5CH(Rsl)CH(Rs2)CH(Rs3)CH(R s4)-, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rk1, Rk2, Rk3, Rk4 and Rk5 are independently H, CH3, or OR2a, and Rs1, Rs2, Rs3, and Rs4 are independently H or CH3, wherein R2a is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbRc, CH2ORd, or CORe; and R5 is H or OR2b, wherein R2b is H, an alkyl group, an aryl group, an aryl group, a benzyl group, a trityl group, -SiRaRbRc, CH2ORd, or CORe; provided that the compound is not dictyostatin 1.

  以下是该结构的化合物：其中R1为H、烷基基团、芳基、烯基基团、炔基基团或卤素原子；R2为H、烷基基团、芳基、苄基、三苄基、-SiRaRbRc、CH2ORd或CORe；Ra、Rb和Rc独立地为烷基基团或芳基；Rd为烷基基团、芳基、烷氧基烷基团、-RiSiRaRbRc或苄基，其中Ri为烷基烷基团；Re为烷基基团、烯丙基基团、苄基、芳基、烷氧基或-NRgRh，其中Rg和Rh独立地为H、烷基基团或芳基；R3为(CH2)n，其中n为0到5范围内的整数，-CH2CH(CH3)-、-CH=CH-、-CH=C(CH3)-或-C=-C-；R4为(CH2)p，其中p为4到12范围内的整数，-(CHRkl)yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5C(Rsl )=C(Rs2)C(Rs3)=C(Rs4)-、-(CHRk1 )yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5CH(Rs I)CH(Rs2)C(Rs3)=C(Rs4)-、-(CHRk1)yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRks)y5C(Rsl)=C(Rs2)CH(Rs3)CH(Rs4)-、-(CHRkI )yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5CH(Rsl)CH(Rs2)CH(Rs3)CH(R s4)-，其中y1和y2为1，y3、y4和y5独立地为0或1，Rk1、Rk2、Rk3、Rk4和Rk5独立地为H、CH3或OR2a，Rs1、Rs2、Rs3和Rs4独立地为H或CH3，其中R2a为H、烷基基团、芳基、苄基、三苄基、-SiRaRbRc、CH2ORd或CORe；R5为H或OR2b，其中R2b为H、烷基基团、芳基、芳基、苄基、三苄基、-SiRaRbRc、CH2ORd或CORe；前提是该化合物不是dictyostatin 1。
• Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof
  申请人：——

  公开号：US20040186165A1

  公开（公告）日：2004-09-23

  A compound of the following structure: 1 wherein R 1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom; R 2 is H, an alkyl group, an aryl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e ; R a , R b and R c are independently an alkyl group or an aryl group; R d is an alkyl group, an aryl group, an alkoxylalkyl group, —R i SiR a R b R c or a benzyl group, wherein R i is an alkylene group; R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or —NR g R h , wherein R g and R h are independently H, an alkyl group or an aryl group; R 3 is (CH 2 ) n where n is and integer in the range of 0 to 5, —CH 2 CH(CH 3 )—, —CH═CH—, —CH═C(CH 3 )—, or —C≡C—; R 4 is (CH 2 ) p where p is an integer in the range of 4 to 12, —(CHR k1 ) y1 (CHR k2 ) y2 (CHR k3 ) y3 (CHR k4 ) y4 (CHR k5 ) y5 C(R s1 )═C(R s2 )C(R s3 )═C(R s4 )—, —(CHR k1 ) y1 (CHR k2 ) y2 (CHR k3 ) y3 (CHR k4 ) y4 (CHR k5 ) y5 CH(R s1 )CH(R s2 )C(R s3 )═C(R s4 )—, —(CHR k1 ) y1 (CHR k2 ) y2 (CHR k3 ) y3 (CHR k4 ) y4 (CHR k5 ) y5 C(R s1 )═C(R s2 )CH(R s3 )CH(R s4 )—, —(CHR k1 ) y1 (CHR k2 ) y2 (CHR k3 ) y3 (CHR k4 ) y4 (CHR k5 ) y5 CH(R s1 )CH(R s2 )CH(R s3 )CH(R s4 )—, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1 , R k2 , R k3 , R k4 and R k5 are independently H, CH 3 , or OR 2a , and R s1 , R s2 , R s3 , and R s4 are independently H or CH 3 , wherein R 2a is H, an alkyl group, an aryl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e ; and R 5 is H or OR 2b , wherein R 2b is H, an alkyl group, an aryl group, an aryl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e ; provided that the compound is not dictyostatin 1.

  以下结构的化合物：其中R1为H、烷基、芳基、烯基、炔基或卤素原子；R2为H、烷基、芳基、苄基、三苯甲基、—SiRaRbRc、CH2ORd或CORe；Ra、Rb和Rc独立地为烷基或芳基；Rd为烷基、芳基、烷氧基烷基、—RiSiRaRbRc或苄基，其中Ri为烷基；Re为烷基、烯丙基、苄基、芳基、烷氧基或—NRgRh，其中Rg和Rh独立地为H、烷基或芳基；R3为(CH2)n，其中n为0至5范围内的整数，—CH2CH(CH3)—、—CH═CH—、—CH═C(CH3)—或—C≡C—；R4为(CH2)p，其中p为4至12范围内的整数，—(CHRk1)y1(CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5C(Rs1)═C(Rs2)C(Rs3)═C(Rs4)—、—(CHRk1)y1(CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5CH(Rs1)CH(Rs2)C(Rs3)═C(Rs4)—、—(CHRk1)y1(CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5C(Rs1)═C(Rs2)CH(Rs3)CH(Rs4)—、—(CHRk1)y1(CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRk5)y5CH(Rs1)CH(Rs2)CH(Rs3)CH(Rs4)—，其中y1和y2为1，y3、y4和y5独立地为0或1，Rk1、Rk2、Rk3、Rk4和Rk5独立地为H、CH3或OR2a，而Rs1、Rs2、Rs3和Rs4独立地为H或CH3，其中R2a为H、烷基、芳基、苄基、三苯甲基、—SiRaRbRc、CH2ORd或CORe；而R5为H或OR2b，其中R2b为H、烷基、芳基、苄基、三苯甲基、—SiRaRbRc、CH2ORd或CORe；但该化合物不是二叉鞘菌素1。
• ANALOGS OF DICODERMOLIDE AND DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF SYNTHESIS THEREOF
  申请人：CURRAN DENNIS P.

  公开号：US20090036691A1

  公开（公告）日：2009-02-05

  A compound of the following structure: wherein R 1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom; R 2 is H, an alkyl group, an aryl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e ; R a , R b and R c are independently an alkyl group or an aryl group; R d is an alkyl group, an aryl group, an alkoxylalkyl group, —R i SiR a R b R c or a benzyl group, wherein R i is an alkylene group; R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or —NR g R h , wherein R g and R h are independently H, an alkyl group or an aryl group; R 3 is (CH 2 ) n where n is and integer in the range of 0 to 5, —CH 2 CH(CH 3 )—, —CH═CH—, —CH═C(CH 3 )—, or —C≡C—; R 4 , wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1 , R k2 , R k3 , R k4 and R k5 are independently H, CH 3 , or OR 2a , and R s1 , R s2 , R s3 , and R s4 are independently H or CH 3 , wherein R 2a is H, an alkyl group, an aryl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e ; and R 5 is H or OR 2b , wherein R 2b is H, an alkyl group, an aryl group, an aryl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e .

  以下为结构式的化合物： 其中R1为H、烷基、芳基、烯基、炔基或卤素原子； R2为H、烷基、芳基、苯甲基、三苯甲基、—SiRaRbRc、CH2ORd或CORe； Ra、Rb和Rc独立地为烷基或芳基； Rd为烷基、芳基、烷氧基烷基、—RiSiRaRbRc或苯甲基，其中Ri为烷基； Re为烷基、烯丙基、苯甲基、芳基、烷氧基或—NRgRh，其中Rg和Rh独立地为H、烷基或芳基； R3为(CH2)n，其中n为0至5的整数，—CH2CH(CH3)—、—CH═CH—、—CH═C(CH3)—或—C≡C—； R4为H或OR2b，其中y1和y2为1，y3、y4和y5独立地为0或1，Rk1、Rk2、Rk3、Rk4和Rk5独立地为H、CH3或OR2a，而Rs1、Rs2、Rs3和Rs4独立地为H或CH3，其中R2a为H、烷基、芳基、苯甲基、三苯甲基、—SiRaRbRc、CH2ORd或CORe；而R2b为H、烷基、芳基、苯甲基、三苯甲基、—SiRaRbRc、CH2ORd或CORe。
• Simplified Discodermolide Analogues:  Synthesis and Biological Evaluation of 4-<i>e</i><i>pi</i>-7-Dehydroxy-14,16-didemethyl-(+)-discodermolides as Microtubule-Stabilizing Agents
  作者：Nakyen Choy、Youseung Shin、Phu Qui Nguyen、Dennis P. Curran、Raghavan Balachandran、Charitha Madiraju、Billy W. Day

  DOI：10.1021/jm0204136

  日期：2003.7.1

  Several novel analogues of (+)-discodermolide were synthesized via a convergent strategy that used Wittig reactions to append left and right side chains to a central scaffold and then tested for biological activity. Three of the analogues in the 4-epi-7-dehydroxy-14,16-didemethyl series, 6a-c, had interesting actions. The C3-methoxymethyl ether analogue 6b was more active in antiproliferative cell-based assays as well as in hypernucleation and paclitaxel site competition assays with isolated tubulin than the other analogues, including 6a, which contained a free hydroxyl group at the C3 position. The biological results validated the initial hypothesis that the C7 hydroxy group and the C14 and C16 methyl groups of (+)-discodermolide could be deleted without undermining activity. Although less potent than (+)-discodermolide and paclitaxel, compounds 6b and 6c both showed properties unique to (+)-discodermolide. These properties, particularly the capacity to cause hypernucleation of isolated tubulin at lower temperature than paclitaxel, as well as stabilizing preformed microtubules to cold disassembly, are considered mechanistically superior to those of paclitaxel. Other variations in the right and left sides of the discodermolide scaffold revealed additional structure/activity information.